Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
IRIDEX Corp Market Cap
From what 1 stock analysts predict, the share price for IRIDEX Corp (IRIX) might decrease by 100% in the next year. This is based on a 12-month average estimation for IRIX. Price targets go from $ to $. The majority of stock analysts believe IRIX is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
IRIX is a stock in Healthcare which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Singular Research and on the lower end IRIX is forecasted to be $ by from Singular Research.
These are the latest 20 analyst ratings of IRIX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Thomas Stephan Stifel | Hold | $2 | Maintains | May 15, 2024 |
| Thomas Stephan Stifel | Hold | $3 | Downgrade | Aug 26, 2022 |
| Scott Henry Roth Capital | Buy | $11 | Maintains | May 12, 2021 |
| Scott Henry Roth Capital | Buy | $9 | Maintains | Mar 3, 2021 |
| Scott Henry Roth Capital | Buy | $6 | Maintains | Jan 13, 2021 |
Stifel | Buy | $4 | Maintains | May 12, 2020 |
| Jonathan Block Stifel | Buy | $7 | Maintains | Jan 4, 2019 |
Stifel Nicolaus | Buy | Maintains | Jan 4, 2019 | |
Stifel | Buy | Initiates | Oct 26, 2018 | |
Stifel Nicolaus | Buy | Initiates | Oct 26, 2018 | |
Roth Capital | Buy | Initiates | Dec 21, 2016 | |
Singular Research | Buy | Initiates | Jan 26, 2016 |
When did it IPO
1996
Staff Count
111
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Patrick Mercer
Market Cap
$29.9M
In 2023, IRIX generated $51.9M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IRIX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iridex Corporation (Nasdaq: IRIX) confirms that Local Coverage Determination L37531 for Micro-Invasive Glaucoma Surgery is effective from November 17, 2024, potentially increasing demand for its treatments.
Why It Matters - The adoption of LCD L37531 could boost demand for Iridex's glaucoma treatments, potentially driving revenue growth and positively impacting stock performance.
Sat, 16 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - IRIDEX Corporation (NASDAQ:IRIX) held its Q3 2024 earnings call on November 12, 2024, with participation from key executives including the Executive Chairman, CEO, and Interim CFO.
Why It Matters - The earnings call indicates upcoming financial performance insights from IRIDEX, which can influence stock price and investor sentiment. Key executives' participation highlights leadership engagement.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iridex Corporation (NASDAQ: IRIX) will release Q3 2024 financial results and a business update on November 12, 2024, after market close.
Why It Matters - The upcoming financial results and business update from Iridex Corporation may influence stock performance and investor sentiment, particularly in the medical technology sector.
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iridex Corporation appointed Patrick Mercer as CEO and President, effective October 1, 2024, following David Bruce's transition. Scott Shuda became Executive Chairman of the board.
Why It Matters - Leadership changes can signal strategic shifts and impact company performance. Mercer’s prior experience may stabilize operations, influencing investor confidence and stock performance.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - IRIDEX is experiencing delays in asset sales amid a strategic review, but aims to complete sales by late 2024. The CEO anticipates potential share price doubling in 3-6 months.
Why It Matters - Delays in asset sales may impact IRIDEX's stock performance, but a commitment to financial sustainability and potential price doubling could attract investor interest.
Sat, 10 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - IRIDEX Corporation (NASDAQ:IRIX) will hold its Q2 2024 Earnings Conference Call on August 8, 2024, at 5:00 PM ET, featuring CEO David Bruce and Interim CFO Fuad Ahmad.
Why It Matters - The Q2 earnings call will provide insights into IRIDEX's financial performance, operational updates, and future guidance, influencing investor sentiment and stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
